Literature DB >> 12183276

Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil.

Ana T Dumans1, Marcelo A Soares, Danuta Pieniazek, Marcia L Kalish, Veronique De Vroey, Kurt Hertogs, Amilcar Tanuri.   

Abstract

The prevalence of mutations that confer resistance to protease inhibitors and to nucleoside and nonnucleoside reverse transcriptase inhibitors in 49 blood samples from drug-naïve human immunodeficiency virus type 1-infected blood donors living in Rio de Janeiro state, Brazil, in 1998 was evaluated genotypically and phenotypically.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12183276      PMCID： PMC127402          DOI： 10.1128/AAC.46.9.3075-3079.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study.

Authors:  S Duwe; M Brunn; D Altmann; O Hamouda; B Schmidt; H Walter; G Pauli; C Kücherer
Journal:  J Acquir Immune Defic Syndr       Date:  2001-03-01       Impact factor: 3.731

2.  World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.

Authors:  P R Harrigan; J S Montaner; S A Wegner; W Verbiest; V Miller; R Wood; B A Larder
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

3.  Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid.

Authors:  C Briones; M Pérez-Olmeda; C Rodríguez; J del Romero; K Hertogs; V Soriano
Journal:  J Acquir Immune Defic Syndr       Date:  2001-02-01       Impact factor: 3.731

4.  Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina.

Authors:  G H Kijak; S E Pampuro; M M Avila; C Zala; P Cahn; M A Wainberg; H Salomón
Journal:  Antivir Ther       Date:  2001-03

5.  Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study.

Authors:  D Descamps; V Calvez; J Izopet; C Buffet-Janvresse; A Schmuck; P Colson; A Ruffault; A Maillard; B Masquelier; J Cottalorda; M Harzic; F Brun-Vézinet; D Costagliola
Journal:  AIDS       Date:  2001-09-28       Impact factor: 4.177

6.  Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites.

Authors:  A J Brown; H M Precious; J M Whitcomb; J K Wong; M Quigg; W Huang; E S Daar; R T D'Aquila; P H Keiser; E Connick; N S Hellmann; C J Petropoulos; D D Richman; S J Little
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: a UNAIDS study.

Authors:  E Delgado; M León-Ponte; M L Villahermosa; M T Cuevas; L Deibis; G Echeverría; M M Thomson; L Pérez-Alvarez; S Osmanov; R Nájera
Journal:  AIDS Res Hum Retroviruses       Date:  2001-05-20       Impact factor: 2.205

8.  Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998.

Authors:  H Weinstock; R Respess; W Heneine; C J Petropoulos; N S Hellmann; C C Luo; C P Pau; T Woods; M Gwinn; J Kaplan
Journal:  J Infect Dis       Date:  2000-06-13       Impact factor: 5.226

9.  Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom.

Authors: 
Journal:  BMJ       Date:  2001-05-05

10.  Genetic heterogeneity of the V3 region of the HIV-1 envelope glycoprotein in Brazil. Brazilian Collaborative AIDS Research Group.

Authors:  K E Potts; M L Kalish; T Lott; G Orloff; C C Luo; M A Bernard; C B Alves; R Badaro; J Suleiman; O Ferreira
Journal:  AIDS       Date:  1993-09       Impact factor: 4.177
View more
  8 in total

1.  Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility.

Authors:  André F A Santos; Denis M Tebit; Matthew S Lalonde; Ana B Abecasis; Annette Ratcliff; Ricardo J Camacho; Ricardo S Diaz; Ottmar Herchenröder; Marcelo A Soares; Eric J Arts
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

2.  Different epidemic potentials of the HIV-1B and C subtypes.

Authors:  Marco Salemi; Tulio de Oliveira; Marcelo A Soares; Oliver Pybus; Ana T Dumans; Anne-Mieke Vandamme; Amilcar Tanuri; Sharon Cassol; Walter M Fitch
Journal:  J Mol Evol       Date:  2005-05       Impact factor: 2.395

3.  Co-infection by human immunodeficiency virus type 1 (HIV-1) and human T cell leukemia virus type 1 (HTLV-1): does immune activation lead to a faster progression to AIDS?

Authors:  Eduardo Samo Gudo; Nilesh B Bhatt; Dulce Ramalho Bila; Celina Monteiro Abreu; Amílcar Tanuri; Wilson Savino; Suse Dayse Silva-Barbosa; Ilesh V Jani
Journal:  BMC Infect Dis       Date:  2009-12-22       Impact factor: 3.090

4.  Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the army health service of Rio de Janeiro, Brazil.

Authors:  Ivone L Pires; Marcelo A Soares; Francisco A B Speranza; Solange K Ishii; Maria C G Vieira; Maria I F S Gouvêa; Maria A A M Guimarães; Fátima E de Oliveira; Monica M F Magnanini; Rodrigo M Brindeiro; Amilcar Tanuri
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

5.  In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.

Authors:  Richard Hazen; Robert Harvey; Robert Ferris; Charles Craig; Phillip Yates; Philip Griffin; John Miller; Istvan Kaldor; John Ray; Vincente Samano; Eric Furfine; Andrew Spaltenstein; Michael Hale; Roger Tung; Marty St Clair; Mary Hanlon; Lawrence Boone
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

6.  Frequency of human immunodeficiency virus type-2 in hiv infected patients in Maputo City, Mozambique.

Authors:  Cremildo Maueia; Deise Costa; Bindiya Meggi; Nalia Ismael; Carla Walle; Raphael Curvo; Celina Abreu; Nilesh Bhatt; Amilcar Tanuri; Ilesh V Jani; Orlando C Ferreira
Journal:  Virol J       Date:  2011-08-17       Impact factor: 4.099

Review 7.  Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis.

Authors:  Santiago Avila-Rios; Omar Sued; Soo-Yon Rhee; Robert W Shafer; Gustavo Reyes-Teran; Giovanni Ravasi
Journal:  PLoS One       Date:  2016-06-29       Impact factor: 3.240

8.  HIV-1 diversity and drug resistance mutations among people seeking HIV diagnosis in voluntary counseling and testing sites in Rio de Janeiro, Brazil.

Authors:  Carlos A Velasco-de-Castro; Beatriz Grinsztejn; Valdiléa G Veloso; Francisco I Bastos; José H Pilotto; Nilo Fernandes; Mariza G Morgado
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.